Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Sulodexide Improves Contraction and Decreases Matrix Metalloproteinase-2 and -9 in Veins under Prolonged Stretch.

Raffetto JD, Yu W, Wang X, Calanni F, Mattana P, Khalil RA.

J Cardiovasc Pharmacol. 2019 Nov 14. doi: 10.1097/FJC.0000000000000778. [Epub ahead of print]

PMID:
31738197
2.

Sulodexide promotes arterial relaxation via endothelium-dependent nitric oxide-mediated pathway.

Raffetto JD, Calanni F, Mattana P, Khalil RA.

Biochem Pharmacol. 2019 Aug;166:347-356. doi: 10.1016/j.bcp.2019.04.021. Epub 2019 Apr 20.

PMID:
31014752
3.

Modulation of the gut microbiota composition by rifaximin in non-constipated irritable bowel syndrome patients: a molecular approach.

Soldi S, Vasileiadis S, Uggeri F, Campanale M, Morelli L, Fogli MV, Calanni F, Grimaldi M, Gasbarrini A.

Clin Exp Gastroenterol. 2015 Dec 4;8:309-25. doi: 10.2147/CEG.S89999. eCollection 2015.

4.

Development of a microarray-based tool to characterize vaginal bacterial fluctuations and application to a novel antibiotic treatment for bacterial vaginosis.

Cruciani F, Biagi E, Severgnini M, Consolandi C, Calanni F, Donders G, Brigidi P, Vitali B.

Antimicrob Agents Chemother. 2015 May;59(5):2825-34. doi: 10.1128/AAC.00225-15. Epub 2015 Mar 2.

5.

Rifaximin: beyond the traditional antibiotic activity.

Calanni F, Renzulli C, Barbanti M, Viscomi GC.

J Antibiot (Tokyo). 2014 Sep;67(9):667-70. doi: 10.1038/ja.2014.106. Epub 2014 Aug 6. Review.

PMID:
25095806
6.

Rifaximin modulates the vaginal microbiome and metabolome in women affected by bacterial vaginosis.

Laghi L, Picone G, Cruciani F, Brigidi P, Calanni F, Donders G, Capozzi F, Vitali B.

Antimicrob Agents Chemother. 2014 Jun;58(6):3411-20. doi: 10.1128/AAC.02469-14. Epub 2014 Apr 7.

7.

Proteome profiles of vaginal fluids from women affected by bacterial vaginosis and healthy controls: outcomes of rifaximin treatment.

Cruciani F, Wasinger V, Turroni S, Calanni F, Donders G, Brigidi P, Vitali B.

J Antimicrob Chemother. 2013 Nov;68(11):2648-59. doi: 10.1093/jac/dkt244. Epub 2013 Jun 24.

PMID:
23798671
8.

Comment on: Rifaximin in the treatment of irritable bowel syndrome. is there a high risk for development of antimicrobial resistance?

Calanni F, Renzulli C, Fogli MV, Barbanti M.

J Clin Gastroenterol. 2013 Oct;47(9):814. doi: 10.1097/MCG.0b013e3182951b6c. No abstract available.

PMID:
23751850
9.

Efficacy of rifaximin vaginal tablets in treatment of bacterial vaginosis: a molecular characterization of the vaginal microbiota.

Cruciani F, Brigidi P, Calanni F, Lauro V, Tacchi R, Donders G, Peters K, Guaschino S, Vitali B.

Antimicrob Agents Chemother. 2012 Aug;56(8):4062-70. doi: 10.1128/AAC.00061-12. Epub 2012 May 14.

10.

Rifaximin modulates the colonic microbiota of patients with Crohn's disease: an in vitro approach using a continuous culture colonic model system.

Maccaferri S, Vitali B, Klinder A, Kolida S, Ndagijimana M, Laghi L, Calanni F, Brigidi P, Gibson GR, Costabile A.

J Antimicrob Chemother. 2010 Dec;65(12):2556-65. doi: 10.1093/jac/dkq345. Epub 2010 Sep 18.

PMID:
20852272
11.
12.

Prevention and therapy of experimental venous thrombosis in rabbits by desmin 370.

Colucci M, Rossiello MR, Barbanti M, Calanni F, Semeraro N.

Thromb Haemost. 1998 Aug;80(2):338-41.

PMID:
9716163
13.

Thrombolysis enhancing activity of a low molecular weight dermatan sulfate (Desmin 370) in experimental pulmonary embolism in rats.

Colucci M, Sardella L, Barbanti M, Calanni F, Semeraro N.

Thromb Res. 1997 Sep 1;87(5):441-6.

PMID:
9306618
14.

Bioavailability of Desmin, a low molecular weight dermatan sulfate, after subcutaneous administration to healthy volunteers.

Miglioli M, Pironi L, Ruggeri E, Serra C, Zamboni V, Barbanti M, Canova N, Calanni F, Milani MR, Palazzini E.

Int J Clin Lab Res. 1997;27(3):195-8.

PMID:
9352383
15.

Desmin 370, a low molecular weight dermatan sulfate, reduces the weight of preformed thrombi in rats made afibrinogenemic by ancrod.

Barbanti M, Calanni F, Marchi E, Semeraro N, Colucci M.

Thromb Haemost. 1995 Feb;73(2):287-90.

PMID:
7792745
16.

Antithrombotic activity of Desmin 370. Comparison with a high molecular weight dermatan sulfate.

Barbanti M, Calanni F, Babbini M, Bergonzini G, Parma B, Marchi E, Wassermann A.

Thromb Res. 1993 Sep 1;71(5):417-22. No abstract available.

PMID:
8236168
17.

Therapeutic effect of a low molecular weight dermatan sulphate (Desmin 370) in rat venous thrombosis--evidence for an anticoagulant-independent mechanism.

Barbanti M, Calanni F, Milani MR, Marchi E, Semeraro N, Colucci M.

Thromb Haemost. 1993 Feb 1;69(2):147-51.

PMID:
8456427
18.

Antithrombotic and thrombolytic activity of sulodexide in rats.

Barbanti M, Guizzardi S, Calanni F, Marchi E, Babbini M.

Int J Clin Lab Res. 1992;22(3):179-84.

PMID:
1520915

Supplemental Content

Loading ...
Support Center